A trio of amy­loid-tar­get­ed Alzheimer's drugs will soon see key re­sults, but an an­a­lyst pre­dicts on­ly 50-50 odds for one

Pig­gy­back­ing off of Bio­gen’s con­tro­ver­sial ac­cel­er­at­ed ap­proval for Aduhelm, new piv­otal da­ta are com­ing soon from three oth­er amy­loid-tar­get­ed Alzheimer’s drugs from Roche, Eli Lil­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER